Talphera (NASDAQ:TLPH) Upgraded at Maxim Group

Maxim Group upgraded shares of Talphera (NASDAQ:TLPH) to a strong-buy rating in a research note published on Friday,Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Talphera in a report on Friday, August 16th.

Talphera Stock Down 2.0 %

Shares of NASDAQ:TLPH opened at $0.89 on Friday. The firm’s 50 day moving average price is $0.91 and its 200-day moving average price is $0.94. Talphera has a twelve month low of $0.43 and a twelve month high of $1.61. The stock has a market capitalization of $15.12 million, a PE ratio of -1.39 and a beta of 0.31.

Talphera (NASDAQ:TLPH) last released its earnings results on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. Analysts expect that Talphera will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Talphera in the second quarter worth $64,000. Nantahala Capital Management LLC purchased a new stake in Talphera during the second quarter valued at about $1,773,000. Finally, Rosalind Advisors Inc. purchased a new stake in Talphera during the third quarter valued at about $650,000. 37.67% of the stock is currently owned by hedge funds and other institutional investors.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.